PMID: 16503317Mar 1, 2006Paper

Effectiveness of the addition of ezetimibe to ongoing statin therapy in modifying lipid profiles and attaining low-density lipoprotein cholesterol goals in older and elderly patients: subanalyses of data from a randomized, double-blind, placebo-controlled trial

The American Journal of Geriatric Pharmacotherapy
Thomas A PearsonJoanne Palmisano

Abstract

The Ezetimibe Add-on to Statin for Effectiveness (EASE) trial examined the effectiveness and safety profile of ezetimibe (EZE) added to ongoing statin therapy in 3030 patients with low-density lipoprotein cholesterol (LDL-C) levels exceeding National Cholesterol Education Program Adult Treatment Panel III (NCEP ATP 111) goals. Because people aged > 65 years are at increased risk for development of coronary heart disease (CHD), these subgroup analyses of data from the EASE trial were conducted to determine the extent of change in LDL-C levels and attainment of NCEP ATP III LDL-C goals with the addition of EZE to ongoing statin therapy in patients aged 65 to 74 years (the older group) and > or = 75 years (the elderly group). In the multicenter (299 sites), community-based, double-blind, placebo-controlled EASE trial, patients were randomly assigned in a 2:1 ratio to receive EZE 10 mg/d or placebo in addition to their ongoing statin therapy for 6 weeks. The primary efficacy end point was the percent reduction in LDL-C levels, and the principal secondary end point was the proportion of patients achieving NCEP ATP III target LDL-C levels. The effects of the addition of EZE on additional lipid and lipoprotein measures and high-sensit...Continue Reading

References

Dec 28, 1999·JAMA : the Journal of the American Medical Association·J C LaRosaS Vupputuri
May 23, 2001·JAMA : the Journal of the American Medical Association·UNKNOWN Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults
Nov 30, 2002·Lancet·James ShepherdUNKNOWN PROSPER study group. PROspective Study of Pravastatin in the Elderly at Risk
Aug 9, 2003·Expert Opinion on Drug Safety·Mohammed H Moghadasian
Apr 22, 2004·JAMA : the Journal of the American Medical Association·Dennis T KoDavid A Alter
Jul 10, 2004·Current Opinion in Lipidology·Moira M B Mungall, Allan Gaw
Sep 18, 2004·International Journal of Clinical Practice·A Gaw
Jan 7, 2005·The New England Journal of Medicine·Paul M RidkerUNKNOWN Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis in Myocardial Infarction 22 (PROVE IT-TIMI 22) Inv

❮ Previous
Next ❯

Citations

Nov 23, 2010·Drugs & Aging·Joseph E ThomasJoAnne M Foody
Feb 13, 2010·Journal of Atherosclerosis and Thrombosis·Shusuke YagiMasataka Sata
Oct 27, 2011·Journal of Atherosclerosis and Thrombosis·Hirotsugu KurobeTetsuya Kitagawa
Feb 18, 2014·Internal Medicine·Tatsuyori MoritaIchiro Shiojima
Jan 8, 2014·Current Atherosclerosis Reports·Parag GoyalWilliam B Borden
Jul 23, 2013·Indian Journal of Endocrinology and Metabolism·Sheelu S SiddiqiAsad U Khan
Oct 22, 2010·Clinical Research in Cardiology : Official Journal of the German Cardiac Society·Anselm K GittKurt Bestehorn
Nov 1, 2005·Current Cardiology Reports·Abu R Vasudevan, Peter H Jones
Oct 28, 2008·Current Cardiology Reports·Maartje E VisserErik S G Stroes
Aug 12, 2006·Current Atherosclerosis Reports·Anders G Olsson
Feb 4, 2006·Current Atherosclerosis Reports·Abu R Vasudevan, Peter H Jones
Apr 1, 2008·Endocrinología y nutrición : órgano de la Sociedad Española de Endocrinología y Nutrición·Enrique González-SarmientoE Inmaculada Fernández-Galante
Oct 30, 2013·Circulation·Jerome L FlegUNKNOWN American Heart Association Committees on Older Populations and Exercise Cardiac Rehabilitation and Prevention of the Council
Nov 16, 2006·Expert Opinion on Therapeutic Targets·Irene F Gazi, Dimitri P Mikhailidis
Dec 22, 2007·Expert Review of Cardiovascular Therapy·Luis Rodríguez Padial
Aug 17, 2019·Laboratory Investigation; a Journal of Technical Methods and Pathology·Gulsum E MukuGary H Perdew
Jun 25, 2014·Nature Reviews. Cardiology·Razvan T Dadu, Christie M Ballantyne
Jan 6, 2018·Expert Review of Clinical Pharmacology·Niki KatsikiDimitri P Mikhailidis

❮ Previous
Next ❯

Related Concepts

Related Feeds

ApoE, Lipids & Cholesterol

Serum cholesterol, triglycerides, apolipoprotein B (APOB)-containing lipoproteins (very low-density lipoprotein (VLDL), immediate-density lipoprotein (IDL), and low-density lipoprotein (LDL), lipoprotein A (LPA)) and the total cholesterol/high-density lipoprotein (HDL) cholesterol ratio are all connected in diseases. Here is the latest research.